UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
|Slideshows|November 4, 2016
Psychiatry Roundup: Tricks or Treatments?
Author(s)Laurie Martin
What do behavioral activation, video therapy, family constellation, ibogaine, and psychomagic have in common? These topics and more were chosen for this month's roundup.
Advertisement
View the information in PDF format.
Advertisement
Related to this article
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
2
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
3
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5